100 项与 Planned Parenthood of Arkansas & Eastern Oklahoma, Inc. 相关的临床结果
0 项与 Planned Parenthood of Arkansas & Eastern Oklahoma, Inc. 相关的专利(医药)
2009-01-01·Infectious Diseases in Obstetrics and Gynecology
Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes
Article
作者: Martens, Mark G. ; Fife, Kenneth H. ; Leone, Peter A. ; Dix, Lynn P. ; Brennan, Clare A.
OBJECTIVE:Genital herpes (GH) recurrences and viral shedding are more frequent in the first year after initial HSV-2 infection. The objective of this study was to provide the first evaluation of valacyclovir 1 g once daily compared to placebo in reducing viral shedding in subjects newly diagnosed with GH.
METHODS:70 subjects were randomized to receive valacyclovir 1 g daily or placebo in a crossover design for 60 days with a 7-day washout period. A daily swab of the genital/anal-rectal area was self-collected for HSV-2 detection by PCR. Subjects attended the clinic for routine study visits and GH recurrence visits. Treatment differences were assessed using a nonparametric crossover analysis.
RESULTS:52 subjects had at least one PCR measurement in both treatment periods and comprised the primary efficacy population. Valacyclovir significantly reduced HSV-2 shedding during all days compared to placebo (mean 2.9% versus 13.5% of all days (P < .01), a 78% reduction). Valacyclovir significantly reduced subclinical HSV-2 shedding during all days compared to placebo (mean 2.4% versus 11.0% of all days (P < .01), a 78% reduction). However, 79% of subjects had no GH recurrences while receiving valacyclovir compared to 52% of subjects receiving placebo (P < .01).
CONCLUSION:In this study, the frequency of total and subclinical HSV-2 shedding was greater than reported in earlier studies involving subjects with a history of symptomatic genital recurrences. Our study is the first to demonstrate a significant reduction in viral shedding with valacyclovir 1 g daily compared to placebo in a population of subjects newly diagnosed with HSV-2 infection.
100 项与 Planned Parenthood of Arkansas & Eastern Oklahoma, Inc. 相关的药物交易
100 项与 Planned Parenthood of Arkansas & Eastern Oklahoma, Inc. 相关的转化医学